Balyasny Asset Management LLC Biomarin Pharmaceutical Inc Transaction History

Balyasny Asset Management LLC

$58 Billion
Q3 2024

A detailed history of Balyasny Asset Management LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Balyasny Asset Management LLC holds 50,000 shares of BMRN stock, worth $3.33 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

50,000

Previous 6,800 635.29%

Holding current value

$3.33 Million

Previous $559,000 528.62%

% of portfolio

0.01%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$69.02 - $93.84 $7.79 Million - $10.6 Million	-112,876 Reduced 11.03%	910,616 $64 Million
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $58.5 Million - $72.5 Million	786,547 Added 331.95%	1,023,492 $84.3 Million
Q1 2024 May 13, 2024	SELL	$83.81 - $99.0 $15.7 Million - $18.6 Million	-187,624 Reduced 44.19%	236,945 $20.7 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $37 Million - $47.9 Million	-485,827 Reduced 53.36%	424,569 $40.9 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $67.5 Million - $75 Million	793,863 Added 681.23%	910,396 $80.6 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $16.4 Million - $19 Million	-189,591 Reduced 61.93%	116,533 $10.1 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $8.64 Million - $11.6 Million	98,520 Added 47.46%	306,124 $29.8 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $46.8 Million - $62.8 Million	-578,184 Reduced 73.58%	207,604 $21.5 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $18.2 Million - $21.4 Million	221,090 Added 39.15%	785,788 $66.6 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $39 Million - $47.4 Million	545,848 Added 2895.75%	564,698 $46.8 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $1.4 Million - $1.75 Million	18,850 New	18,850 $1.45 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $1.48 Million - $1.67 Million	-19,657 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $10.7 Million - $13 Million	-143,752 Reduced 87.97%	19,657 $1.48 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $9.21 Million - $11.4 Million	126,828 Added 346.7%	163,409 $14.3 Million
Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $5.05 Million - $9.2 Million	-70,245 Reduced 65.76%	36,581 $2.78 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $20.6 Million - $32.2 Million	-259,466 Reduced 70.84%	106,826 $13.2 Million
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $18.4 Million - $25 Million	-258,125 Reduced 41.34%	366,292 $31 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $30.7 Million - $41.2 Million	477,401 Added 324.73%	624,417 $52.8 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $17.6 Million - $22.2 Million	-260,750 Reduced 63.95%	147,016 $9.91 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $31.6 Million - $36.9 Million	393,462 Added 2750.71%	407,766 $34.9 Million
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $18.4 Million - $21.5 Million	-218,287 Reduced 93.85%	14,304 $1.27 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $23.3 Million - $30.8 Million	-290,220 Reduced 55.51%	232,591 $19.8 Million
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $9.96 Million - $11.2 Million	106,041 Added 25.44%	522,811 $50.7 Million
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $47.2 Million - $61.6 Million	-621,529 Reduced 59.86%	416,770 $39.3 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $55.4 Million - $66.1 Million	-713,092 Reduced 40.72%	1,038,299 $84.2 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $55.7 Million - $65.6 Million	689,779 Added 64.97%	1,751,391 $156 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $85.6 Million - $101 Million	1,061,612	1,061,612 $98.8 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account

Balyasny Asset Management LLC Biomarin Pharmaceutical Inc Transaction History